$SLS

SELLAS Life Sciences (SLS) is approaching the 80-death event trigger for its Phase 3 REGAL trial and continues enrollment in the Phase 2 SLS009 trial, with initial data expected in Q4. The stock rose 7% to $12.31, ending a three-quarter decline, as traders noted its HQ lease and upcoming milestones.

Sellas Life Sciences (SLS) fell 16.6% in Q3 due to delays in AML treatment data. Despite this, shares rose 6.95% on Q3 window-dressing. The company's GPS treatment study awaits the 80th patient death for results. SLS009 showed promising data in pancreatic cancer trials. Q2 losses widened to $9.6M, with no revenue. Hedge funds increased holdings to $79.7M, with Anson Investments as the largest stakeholder.

Sellas Life Sciences (SLS) stock rose 2% to $13.76 after updating its SLS009 trial for AML, which includes drugs from AbbVie (ABBV), Roche (RHHBY), and Bristol Myers Squibb (BMY). The trial, in early-to-mid stages, tests SLS009 alone and in combination. SLS focuses on its Phase 3 Regal trial, nearing final analysis. CEO Angelos Stergiou addressed criticism, emphasizing data over noise. Retail sentiment remains bullish.

Johnson & Johnson and Pfizer are targeting early-stage cancer assets, focusing on Sellas Life Sciences (SLS), ImmunityBio (IBRX), and Iovance Biotherapeutics (IOVA). SLS's SLS009 showed 46%-50% response rates in AML, while Iovance expects lung-cancer data in Q4. J&J's CEO highlighted M&A interest in early-stage opportunities, with recent deals like Halda Therapeutics and Firefly Bio. IOVA, IBRX, and SLS stocks rose 8%, 6%, and 2% respectively on Monday.

U.S. stock futures dropped due to U.S.-Iran tensions, overshadowing earnings season and economic data. Nasdaq futures fell 1.2%, S&P 500 futures declined 0.4%. SK Hynix (SKHYV) fell 15% post-debut. Oil stocks rose on geopolitical risks. Micron (MU) and Tesla (TSLA) dropped on profit-taking and competitive pressures. Microsoft (MSFT) saw defensive buying.

Sellas Life Sciences (SLS) reported increased cash reserves to $135.8 million after warrant exercises, extending its capital runway. CEO Angelos Stergiou highlighted this as enabling key milestones and growth. The company's shares were down 2.5% at the time of writing. Investors focus on the Regal trial of Galinpepimut-S (GPS) in AML, with 78 of 80 events recorded, and SLS009, a Phase 2 AML drug candidate with data expected later this year.

Sellas Life Sciences (SLS) shares rose 0.3% overnight after CEO Angelos Stergiou's LinkedIn update, which mentioned a 'quiet period' and 'database lock,' sparked takeover speculation. The company is nearing the 80th event in its Phase 3 Regal trial for AML treatment. Stergiou clarified that the slower event rate does not indicate stronger survival. Investors are interpreting the update as potential buyout signals, with SLS stock up 605% over the past year.

U.S. stock futures rose on Sunday after reports that the U.S. and Iran agreed to pause military strikes and resume talks. S&P 500, Dow, and Nasdaq futures gained 0.45%, 0.22%, and 0.43% respectively. Geopolitical tensions had escalated following Iran's attacks on ships and U.S. retaliations. Key economic data releases are expected this week. Specific stocks mentioned include SLS, WEN, MSTR, and WDC.

U.S. stock futures rose early Thursday, with Dow up 0.4% and S&P 500 up 0.2%, ahead of PPI data and jobless claims. NVDA faced SEC filings and DOJ scrutiny, AAPL launched new iPhones, META acquired Stilla.ai, TSM reported 53.3% sales jump, and TSLA faced EV market concerns. Key earnings: ORCL, ADBE.

SELLAS Life Sciences (SLS) fell 14.4% on Friday, with no new company filings or clinical news disclosed. The drop is attributed to traders reducing risk ahead of two upcoming clinical milestones: the REGAL Phase 3 study and the SLS009 Phase 2 trial. SLS closed at $11.545, with volume rising to 14.6 million shares. The company has $138.3 million in cash and expects it to last at least 12 months.